Extensive research has confirmed the association of the NF‐κB pathway with SLE pathogenesis, especially in SLE‐associated nephritis and neuropsychiatric lupus, where therapeutic targeting of NF‐κB has shown efficacy [30, 31, 32]. Here, NFKB1 is linked to systemic lupus erythematosus.